- Home
- GSL vs IMTX Comparison
GSL vs IMTX Comparison
Compare GSL & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GSL | IMTX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | Greece | Germany |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | GSL | IMTX |
|---|---|---|
| Price | $34.87 | $9.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $39.00 | $19.25 |
| AVG Volume (30 Days) | 358.1K | ★ 557.4K |
| Earning Date | 11-10-2025 | 11-17-2025 |
| Dividend Yield | ★ 7.16% | N/A |
| EPS Growth | ★ 24.38 | N/A |
| EPS | ★ 11.14 | N/A |
| Revenue | ★ $747,044,000.00 | $99,445,031.00 |
| Revenue This Year | $6.69 | N/A |
| Revenue Next Year | N/A | $19.39 |
| P/E Ratio | $3.13 | ★ N/A |
| Revenue Growth | ★ 6.50 | N/A |
| 52 Week Low | $17.73 | $3.30 |
| 52 Week High | $37.22 | $12.41 |
Technical Indicators
Market Signals| Indicator | GSL | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 42.19 |
| Support Level | $34.15 | $9.89 |
| Resistance Level | $35.49 | $10.90 |
| Average True Range (ATR) | 0.68 | 0.51 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 74.18 | 19.21 |
Price Performance
Historical ComparisonAbout GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.